Literature DB >> 12840682

A pilot trial of Saccharomyces boulardii in ulcerative colitis.

Mario Guslandi1, Patrizia Giollo, Pier Alberto Testoni.   

Abstract

OBJECTIVES: Probiotics can be useful in the treatment of inflammatory bowel disease. In a previous report, the non-pathogenic yeast Saccharomyces boulardii was found to be beneficial in the maintenance treatment of Crohn's disease. The aim of this study was to assess the efficacy of S. boulardii in ulcerative colitis patients.
METHODS: A group of 25 patients with a mild to moderate clinical flare-up of ulcerative colitis received additional treatment with S. boulardii 250 mg three times a day for 4 weeks during maintenance treatment with mesalazine. These patients were unsuitable for steroid therapy. Before and after treatment, Rachmilewitz's clinical activity index was calculated. The probiotic treatment was considered a therapeutic success only when the final score was lower than 6.
RESULTS: Of the 24 patients who completed the study, 17 attained clinical remission; this was confirmed endoscopically.
CONCLUSIONS: Our preliminary results suggest that S. boulardii can be effective in the treatment of ulcerative colitis. Controlled studies with this probiotic agent are warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12840682     DOI: 10.1097/00042737-200306000-00017

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  66 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 2.  Role of the gut microbiota in defining human health.

Authors:  Kei E Fujimura; Nicole A Slusher; Michael D Cabana; Susan V Lynch
Journal:  Expert Rev Anti Infect Ther       Date:  2010-04       Impact factor: 5.091

Review 3.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models.

Authors:  Sandra Nell; Sebastian Suerbaum; Christine Josenhans
Journal:  Nat Rev Microbiol       Date:  2010-07-12       Impact factor: 60.633

4.  In vitro investigation of Debaryomyces hansenii strains for potential probiotic properties.

Authors:  Honeylet Sabas Ochangco; Amparo Gamero; Ida M Smith; Jeffrey E Christensen; Lene Jespersen; Nils Arneborg
Journal:  World J Microbiol Biotechnol       Date:  2016-07-18       Impact factor: 3.312

5.  Manipulation of enteric flora in ulcerative colitis.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

Review 6.  Probiotics in the management of inflammatory bowel disease.

Authors:  Robert M Penner; Richard N Fedorak
Journal:  MedGenMed       Date:  2005-07-18

7.  Targeting intestinal microflora in inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

Review 8.  Antibiotics and probiotics in treatment of inflammatory bowel disease.

Authors:  Paolo Gionchetti; Fernando Rizzello; Karen-M Lammers; Claudia Morselli; Lucia Sollazzi; Samuel Davies; Rosy Tambasco; Carlo Calabrese; Massimo Campieri
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

Review 9.  Probiotics and prebiotics in chronic inflammatory bowel diseases.

Authors:  Julia B Ewaschuk; Levinus A Dieleman
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

Review 10.  Probiotics in the management of colonic disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2007-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.